Sugi Predict

Sugi Predict / Compounds / SCHEMBL16805280

SCHEMBL16805280

SCHEMBL16805280

Cc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)OP(=O)(O)OP(=O)(O)O)C(O)[C@@H]2N)c(=O)[nH]1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RX3 P56373 4/20 0.66
▸ P2RX1 P51575 2/20 0.66
▸ P2RX2 Q9UBL9 2/20 0.66
▸ P2RY2 P41231 2/20 0.59
▸ P2RY4 P51582 2/20 0.59
▸ TGM2 P21980 1/20 0.59
▸ ENPP1 P22413 2/20 0.58
▸ P2RY1 P47900 2/20 0.58
▸ P2RY6 Q15077 2/20 0.58
▸ P2RY11 Q96G91 1/20 0.58
▸ P2RX4 Q99571 1/20 0.58
▸ IMPDH2 P12268 5/20 0.58
▸ IMPDH1 P20839 1/20 0.58
▸ RNASEL Q05823 1/20 0.57
▸ FUT5 Q11128 1/20 0.57
▸ P2RY12 Q9H244 1/20 0.57
▸ KRAS P01116 2/20 0.56
▸ TAS1R3 Q7RTX0 1/20 0.55
▸ TAS1R1 Q7RTX1 1/20 0.55
▸ NT5E P21589 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15746483 1.00 P2RX3 (0.66) P2RX3P2RX1P2RX2P2RY2P2RY4
SCHEMBL18289612 0.92 P2RX3 (0.68) P2RX3P2RX1P2RX2TGM2ENPP1
SCHEMBL18158963 0.92 P2RX3 (0.68) P2RX3P2RX1P2RX2TGM2ENPP1
SCHEMBL18269536 0.92 P2RX3 (0.68) P2RX3P2RX1P2RX2TGM2ENPP1
SCHEMBL15747234 0.91 TGM2 (0.71) P2RX3P2RX1P2RX2P2RY2P2RY4
SCHEMBL4379787 0.91 TGM2 (0.71) P2RX3P2RX1P2RX2P2RY2P2RY4
SCHEMBL20850287 0.91 TGM2 (0.71) P2RX3P2RX1P2RX2P2RY2P2RY4
SCHEMBL17160788 0.91 TGM2 (0.71) P2RX3P2RX1P2RX2P2RY2P2RY4
SCHEMBL15746465 0.90 P2RX3 (0.58) P2RX3P2RX1P2RX2TGM2ENPP1
SCHEMBL16805282 0.90 P2RX3 (0.58) P2RX3P2RX1P2RX2TGM2ENPP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12023371-B2 Terminally modified RNA MODERNATX, INC. (US) 2024-07-02 — — US disclosed
US-20180000910-A1 TERMINALLY MODIFIED RNA ARES CAPITAL CORPORATION, AS AGENT 2018-01-04 — — US disclosed
US-9751925-B2 Alternative nucleic acid molecules containing reduced uracil content and uses thereof MODERNATX, INC. (US) 2017-09-05 — — US disclosed
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2017-06-22 — — US disclosed
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2017-05-18 — — US disclosed
US-20160354490-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 — — US disclosed
US-20160354492-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 — — US disclosed
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-08 — — US disclosed
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2016-12-01 — — US disclosed
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2016-10-20 — — US disclosed
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2016-09-15 — — US disclosed
US-20160237108-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF ARES CAPITAL CORPORATION, AS AGENT 2016-08-18 — — US disclosed
US-20160237134-A1 ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF ARES CAPITAL CORPORATION, AS AGENT 2016-08-18 — — US disclosed
US-20150167017-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2015-06-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160354492-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 P2RX3 3314/4885P2RX1 3638/4885P2RX2 3939/4885
US-20160264614-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF POLRMT, POLN, NSUN3 P2RX3 846/4885P2RX1 1107/4885P2RX2 1153/4885
US-20160304552-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 P2RX3 3314/4885P2RX1 3638/4885P2RX2 3939/4885
US-20180000910-A1 TERMINALLY MODIFIED RNA RNGTT, NSUN3, RNMT P2RX3 4386/4885P2RX1 4638/4885P2RX2 4750/4885
US-20160348099-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 P2RX3 3314/4885P2RX1 3638/4885P2RX2 3939/4885
US-20170136132-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 P2RX3 2081/4885P2RX1 2820/4885P2RX2 3031/4885
US-20160354490-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 P2RX3 3314/4885P2RX1 3638/4885P2RX2 3939/4885
US-20160237134-A1 ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF RNMT, NSUN2, ADAR P2RX3 957/4885P2RX1 1167/4885P2RX2 1126/4885
US-20160354491-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, ADAR, NSUN3 P2RX3 3314/4885P2RX1 3638/4885P2RX2 3939/4885
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 P2RX3 2081/4885P2RX1 2820/4885P2RX2 3031/4885
US-12023371-B2 Terminally modified RNA RNGTT, NSUN3, RNMT P2RX3 4386/4885P2RX1 4638/4885P2RX2 4750/4885
US-20160237108-A1 POLYNUCLEOTIDE MOLECULES AND USES THEREOF NSUN3, POLRMT, TRDMT1 P2RX3 1830/4885P2RX1 2215/4885P2RX2 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.